Kit Erlebach

Senior Director, Engineering & BIA MAC Chair, FUJIFILM Biotechnologies

Kit is responsible for Engineering and EHS at FUJIFILM Biotechnologies in the UK. Kit has also worked as a Biochemical Engineer for 20 years and holds a Lean Six Sigma leader Master Black Belt qualification. He has applied LSS to quality, engineering and manufacturing in the course of leading laboratory construction projects totalling more than £100M. Kit has a first degree from Nottingham University in Chemical Engineering and a PhD from Cambridge University in Chemical Engineering and is a Fellow of the Institute of Chemical Engineers. He an MBA from the Open University as part of the ATAC programme.

Ian McCubbin

Chair of RoslinCT, Chair of Cell and Gene Therapy Catapult

Chair of RoslinCT and Chair of Cell and Gene Therapy Catapult; Chair of Manufacturing Advisory Group for IUK Industrial Challenge Fund; Member of the UK Government Vaccines Task Force. Ian retired from his role as SVP North America, Japan & Global Pharma Supply, GSK in April 2017. He joined GSK in 2006, his second spell with the company and was responsible for 17 factories and 7,000 employees globally whose role within GSK was to supply the New Product pipeline and the majority of GSK's pharmaceutical sales. Ian chaired the Advanced Therapy Manufacturing Task Force originally co-chaired with George Freeman, Minister for Life Sciences and the group published its Action Plan to 'anchor' commercial scale manufacturing in the UK. The Action Plan has subsequently been adopted in full as part of the Life Sciences Industrial Strategy. He led the manufacturing work stream of the UK Vaccines Task Force between March 2020 and May 2021. Ian is a pharmacist with 40 years of experience in the Pharmaceutical industry working for GSK, Merck Generics and IVAX. His core capability is in the field of manufacturing and supply chain leadership and new product introduction. His passion is cell and gene therapies due to their transformational medical benefits and the opportunity they create for UK economic benefit.